How the OneStep Partnership Could Drive Growth for ZBH Stock
Summarize this article with:
December 17, 2025 — 07:58 am EST Written by Zacks Equity Research for Zacks-> Zimmer Biomet Holdings, Inc. ZBH recently inked an exclusive collaboration agreement with OneStep, the FDA-listed digital fall prevention and mobility intelligence platform. The collaboration is aimed at delivering a comprehensive set of mobility data to further empower surgeons to track recovery progress more effectively following joint replacement surgery. Following the announcement, Zimmer Biomet shares slipped 1.6% yesterday. On a promising note, the collaboration underscores the company’s ongoing commitment to advancing innovations that help surgeons safely and efficiently tackle complex clinical problems. We expect the news to help enable a rebound in ZBH stock’s performance.Zimmer Biomet has a market capitalization of $18.02 billion. The company’s earnings yield of 8.3% compares favorably with the industry 0.2% yield. In the trailing four quarters, it delivered an average earnings surprise of 2.2%.The collaboration will use OneStep's gait and mobility analytics that are captured on both iPhone and Android smartphones and integrate the data directly into Zimmer Biomet's mymobility Care Management Platform for orthopedic surgery patients. Users of mymobility will have access to daily, objective insights across their joint replacement journey, from surgical preparation through recovery using their smartphones. The integration enables remote assessment of gait and functional mobility powered by OneStep's clinically validated technology, delivered seamlessly through the mymobility app. For investors’ note, Zimmer Biomet’s mymobility Care Management Platform provides a guided orthopedic patient experience, including education, surveys, check-ins, messaging, and video-guided post-operative exercises, among other features — all supported by automation, data, and insights that enable surgeons to monitor patients’ recovery progress.OneStep's gait and mobility integration supports Zimmer Biomet's broader connected care strategy, which links technology, data and digital tools across the patient journey. Powered by analysis of more than 1 million gait cycles every day, OneStep's mobility intelligence provides one of the world's largest real-world mobility datasets. By embedding OneStep’s mobility intelligence, Zimmer Biomet enhances its ability to monitor recovery trends, quantify patient function, and support clinicians in tailoring rehabilitation programs using objective, real-world insights.Image Source: Zacks Investment ResearchPer a report by Grand View Research, the global joint replacement market size was valued at $17.1 billion in 2020 and is expected to reach $25.4 billion by 2028, expanding at a compound annual growth rate (CAGR) of 3.4% from 2021 to 2028. The increase in the prevalence of orthopedic disorders, osteoporosis and lower extremity conditions is driving the market for joint replacement.Last month, Zimmer Biomet received FDA 510(k) clearance for its ROSA Knee with OptimiZe, an enhanced version of its ROSA Knee System. The system offers a more customized experience for surgeons to help deliver accurate and reproducible outcomes in robotic-assisted total knee replacement surgery.Over the past year, ZBH shares have lost 15.9% compared to the industry’s 0.5% growth.Zimmer Biomet currently carries a Zacks Rank #3 (Hold).Some better-ranked stocks in the broader medical space are BrightSpring Health Services BTSG, Illumina ILMN and Omnicell OMCL, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.Estimates for BrightSpring Health Services’ 2025 EPS have increased 5.7% in the past 30 days. Shares of the company have surged 92.3% over the past year compared with the industry’s 1.1% growth. BTSG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 45.1%. In the last reported quarter, it delivered an earnings surprise of 11.1%. Illumina shares have lost 9.4% over the past year. Estimates for the company’s 2025 EPS have increased 0.9% to $4.71 in the past 30 days. ILMN’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 6.7%. In the last reported quarter, it posted an earnings surprise of 15.5%.Omnicell’s shares have lost 13.9% over the past year. Estimates for the company’s 2025 EPS have increased 8.3% to $1.70 in the past 30 days. OMCL’s earnings topped estimates in each of the trailing four quarters, delivering an average surprise of 38.7%. In the last reported quarter, it posted an earnings surprise of 41.7%. Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportOmnicell, Inc. (OMCL) : Free Stock Analysis ReportIllumina, Inc. (ILMN) : Free Stock Analysis ReportZimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis ReportBrightSpring Health Services, Inc. (BTSG) : Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchThe views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.This data feed is not available at this time.